Marker Therapeutics (MRKR) Competitors $3.66 -0.39 (-9.63%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends MRKR vs. IVA, FTLF, SKYE, TELO, CRDF, VXRT, IXHL, ADAG, PBYI, and OTLKShould you be buying Marker Therapeutics stock or one of its competitors? The main competitors of Marker Therapeutics include Inventiva (IVA), FitLife Brands (FTLF), Skye Bioscience (SKYE), Telomir Pharmaceuticals (TELO), Cardiff Oncology (CRDF), Vaxart (VXRT), Incannex Healthcare (IXHL), Adagene (ADAG), Puma Biotechnology (PBYI), and Outlook Therapeutics (OTLK). These companies are all part of the "pharmaceutical products" industry. Marker Therapeutics vs. Inventiva FitLife Brands Skye Bioscience Telomir Pharmaceuticals Cardiff Oncology Vaxart Incannex Healthcare Adagene Puma Biotechnology Outlook Therapeutics Inventiva (NASDAQ:IVA) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, community ranking, valuation, earnings and profitability. Is IVA or MRKR more profitable? Inventiva has a net margin of 0.00% compared to Marker Therapeutics' net margin of -278.27%. Inventiva's return on equity of 0.00% beat Marker Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets InventivaN/A N/A N/A Marker Therapeutics -278.27%-78.91%-66.10% Do analysts rate IVA or MRKR? Inventiva currently has a consensus target price of $17.67, indicating a potential upside of 542.42%. Marker Therapeutics has a consensus target price of $19.00, indicating a potential upside of 419.13%. Given Inventiva's higher probable upside, equities analysts plainly believe Inventiva is more favorable than Marker Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inventiva 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Marker Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, IVA or MRKR? Inventiva has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Does the media refer more to IVA or MRKR? In the previous week, Inventiva had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 2 mentions for Inventiva and 0 mentions for Marker Therapeutics. Inventiva's average media sentiment score of 0.72 beat Marker Therapeutics' score of 0.00 indicating that Inventiva is being referred to more favorably in the media. Company Overall Sentiment Inventiva Positive Marker Therapeutics Neutral Does the MarketBeat Community favor IVA or MRKR? Marker Therapeutics received 53 more outperform votes than Inventiva when rated by MarketBeat users. However, 82.61% of users gave Inventiva an outperform vote while only 63.72% of users gave Marker Therapeutics an outperform vote. CompanyUnderperformOutperformInventivaOutperform Votes1982.61% Underperform Votes417.39%Marker TherapeuticsOutperform Votes7263.72% Underperform Votes4136.28% Do institutionals & insiders have more ownership in IVA or MRKR? 19.1% of Inventiva shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 32.0% of Inventiva shares are held by company insiders. Comparatively, 17.4% of Marker Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better valuation & earnings, IVA or MRKR? Marker Therapeutics has lower revenue, but higher earnings than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInventiva$18.91M7.63-$119.51MN/AN/AMarker Therapeutics$3.31M9.86-$8.24MN/AN/A SummaryInventiva beats Marker Therapeutics on 10 of the 15 factors compared between the two stocks. Ad Porter & CompanyThis is treasonIf you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Marker Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRKR vs. The Competition Export to ExcelMetricMarker TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.14M$7.42B$5.54B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E RatioN/A9.93114.8115.14Price / Sales9.86396.631,495.55100.10Price / CashN/A47.3939.6734.08Price / Book2.325.324.665.02Net Income-$8.24M$153.56M$119.06M$225.46M7 Day Performance-15.38%0.13%0.80%0.37%1 Month Performance41.31%15.23%5.65%3.57%1 Year Performance16.93%41.14%36.75%29.43% Marker Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRKRMarker Therapeutics3.5627 of 5 stars$3.66-9.6%$19.00+419.1%+28.9%$36.14M$3.31M0.0060Gap UpIVAInventiva2.7425 of 5 stars$2.76+1.8%$17.67+540.1%-26.5%$144.84M$15.62M0.00100Gap DownFTLFFitLife Brands3.906 of 5 stars$31.49+0.8%$40.00+27.0%+44.0%$144.79M$60.68M19.5620SKYESkye Bioscience1.6381 of 5 stars$5.15+2.4%$18.67+262.5%+247.5%$144.55MN/A0.0011Gap UpTELOTelomir PharmaceuticalsN/A$4.87-0.8%N/AN/A$144.20MN/A0.001Positive NewsGap UpCRDFCardiff Oncology1.0788 of 5 stars$3.09+3.3%$9.67+212.8%+205.2%$143.84M$665,000.00-3.4020Upcoming EarningsShort Interest ↑News CoverageVXRTVaxart1.9345 of 5 stars$0.80-3.7%$3.00+272.9%+19.2%$142.28M$15.65M-1.75109Upcoming EarningsNews CoverageIXHLIncannex Healthcare1.0187 of 5 stars$2.23-0.9%N/A+148.8%$141.56M$12,000.000.003Gap UpADAGAdagene3.2917 of 5 stars$3.15+4.3%$5.00+58.7%+127.6%$139.10M$815,746.000.00260Positive NewsGap DownPBYIPuma Biotechnology2.4928 of 5 stars$2.78-1.8%$7.00+151.8%+11.3%$136.36M$235.60M14.63185Upcoming EarningsAnalyst UpgradeNews CoverageOTLKOutlook Therapeutics1.6109 of 5 stars$5.74-0.3%$48.20+739.7%-52.2%$135.79MN/A-0.5420Positive News Related Companies and Tools Related Companies Inventiva Alternatives FitLife Brands Alternatives Skye Bioscience Alternatives Telomir Pharmaceuticals Alternatives Cardiff Oncology Alternatives Vaxart Alternatives Incannex Healthcare Alternatives Adagene Alternatives Puma Biotechnology Alternatives Outlook Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MRKR) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marker Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
